个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Li, Chunrui[1] * ; Qiu, Lu-Gui[2] ; Wang, Di[1] ; Song, Yongping[3] ; Huang, He[4] ; Li, Jianyong[5] ; Chen, Bing[6] ; Liu, Jing[7] ; Dong, Yujun[8] ; Hu, Kai[9] ; Liu, Peng[10] ; Zhang, Xi[11] ; Mi, Jianqing[12] ; Li, Zhenyu[13] ; Ding, Kaiyang[14] ; Zhang, Shiyue[15] ; Hu, Guang[15] ; Wang, Wen[15] ;
单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Hematol, Wuhan, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst,Inst Hematol & Blood Dis H, Tianjin, Peoples R China [3]Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China [4]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China [5]Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Hematol, Nanjing, Peoples R China [6]Nanjing Univ, Sch Med, Affiliated Hosp, Dept Hematol,Nanjing Drum Tower Hosp, Nanjing, Peoples R China [7]Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China [8]Peking Univ First Hosp, Dept Hematol, Beijing, Peoples R China [9]Beijing Boren Hosp, Dept Adult Lymphoma, Beijing, Peoples R China [10]Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China [11]Army Med Univ, Affiliated Xinqiao Hosp, Chongqing, Peoples R China [12]Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp,State Key Lab Med Genom, Shanghai Inst Hematol,Natl Res Ctr Translat Med S, Shanghai, Peoples R China [13]Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China [14]Univ Sci & Technol China, Affiliated Hosp 1, Dept Hematol, Hefei, Anhui, Peoples R China [15]Nanjing IASO Biotherapeut Ltd, Nanjing, Peoples R China
出处：
DOI： 10.1182/blood-2023-173427
ISSN：
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 血液学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 血液学
JCR分区：
出版当年[2021]版：
Q1 HEMATOLOGY
最新[2023]版：
Q1 HEMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Hematol, Wuhan, Peoples R China
推荐引用方式(GB/T 7714)：
Li Chunrui,Qiu Lu-Gui,Wang Di,et al.Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1[J].BLOOD.2023,142:doi:10.1182/blood-2023-173427.
APA：
Li, Chunrui,Qiu, Lu-Gui,Wang, Di,Song, Yongping,Huang, He...&Wang, Wen.(2023).Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1.BLOOD,142,
MLA：
Li, Chunrui,et al."Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1".BLOOD 142.(2023)

资源点击量：590 今日访问量：1 总访问量：442 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）